## **WE CLAIM:**



1. A method for treating a patient suffering from or predisposed to developing an inflammatory respiratory disorder, comprising administering to the patient a pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing.

15

4

- 2. The method of claim 1, wherein the active agent is *cis*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.
  - 3. The method of claim 2, wherein the active agent is *cis*-resveratrol.
- 4. The method of claim 2, wherein the active agent is a conjugate of *cis*-resveratrol and a mono- or di-saccharide.
- 5. The method of claim 4, wherein the active agent is *cis*-resveratrol glucoside.

20

- 6. The method of claim 1, wherein the active agent is *trans*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.
  - 7. The method of claim 6, wherein the active agent is *trans*-resveratrol.

25

8. The method of claim 6, wherein the active agent is a conjugate of *trans*-resveratrol and a mono- or di-saccharide.

5

- 9. The method of claim 8, wherein the active agent is trans-resveratrol glucoside.
- 10. The method of claim 1, wherein the active agent comprises a mixture of cis-resveratrol and trans-resveratrol.
  - 11. The method of claim 1, wherein the active agent is delivered orally.
- 12. The method of claim 1, wherein the active agent is delivered by pulmonary administration.
  - 13. The method of claim 1, wherein the active agent is delivered parenterally.
- 14. The method of claim 13, wherein the active agent is delivered to the alveoli.
  - 15. The method of claim 1, wherein the disorder is asthma.
  - 16. The method of claim 1, wherein the disorder is atopic asthma.
  - 17. The method of claim 1, wherein the disorder is non-atopic asthma.
  - 18. The method of claim 1, wherein the disorder is COPD.
  - 19. The method of clatin 1, wherein the disorder is alveolitis.

10

15

4

20

25

20. The method of claim 1, wherein the disorder is interstitial lung disease (ILD).

21. The method of claim 1, wherein the disorder is a result of occupational or environmental exposure is to smoke, an organic or inorganic dust, or an allergen.

22. The method of claim 21, wherein the disorder is a result of occupational or environmental exposure is to an organic or inorganic dust.

23. The method of claim 22, wherein the organic or inorganic dust is derived from one or more materials selected from the group consisting of silica, asbestos, beryllium, coal, carbon, wood, starch, sugar, flour, synthetic polymers, cellulosic materials, clay concrete, lime and earth.

24. The method of claim 1, further comprising the co-administration of an additional active agent.

25. The method of claim 24, wherein the formulation further includes an additional active agent.

26. The method of claim 25, wherein the additional active agent is selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.

Up?

132 B

15

ij.

20

25

23/2 23/3

27. The method of claim 26, wherein the wherein the additional active agent is selected from the group consisting of phosphodiesterase inhibitors, long acting  $\beta_2$  adrenergic agonists, and combinations thereof.

5 HB2

28. The method of claim 27, wherein the additional active agent is selected from the group consisting of the ophylline, salmetrol xinafoate, and a combination thereof.

10

29. A pharmaceutical formulation for treatment of an inflammatory respiratory disorder, comprising a first active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing, and a second active agent selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, and combinations thereof.

30. A pharmaceutical formulation for pulmonary administration, comprising an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and a carrier suitable for pulmonary drug administration.

20

add (